How HUTCHMED (China) Limited is positioning HMPL-760 against established BTK therapies in lymphoma care
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.
How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.
Incyte’s tafasitamab clears pivotal trial in high-risk DLBCL—will it shift front-line treatment?
Incyte Corporation has announced positive topline results from its Phase 3 frontMIND trial evaluating tafasitamab (marketed as Monjuvi/Minjuvi) and lenalidomide in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and a key secondary endpoint of event-free survival (EFS), setting the stage for […]